S&P Futures
3,892.00+24.50(+0.63%)Dow Futures
31,588.00+230.00(+0.73%)Nasdaq Futures
13,145.75+90.50(+0.69%)
Lantheus Holdings, Inc. (LNTH)
Chart Events
Performance Outlook
| Previous Close | 19.03 |
| Open | 19.01 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 1800 |
| Day's Range | 18.31 - 19.24 |
| 52 Week Range | 8.67 - 20.29 |
| Volume | 441,643 |
| Avg. Volume | 558,427 |
| Market Cap | 1.226B |
| Beta (5Y Monthly) | 1.08 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.25 |
| Earnings Date | Feb 25, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.20 |
Fair Value
Related Research
- Business Wire
Lantheus Announces Publication of PyLâ„¢ (18F-DCFPyL) Results from Pivotal Studies
Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, today announced the publication of the results of both pivotal studies for PyLâ„¢, an investigational PET imaging agent that targets prostate-specific membrane antigen (PSMA). The OSPREY Phase 2/3 trial results have been published online in the Journal of Urology and the CONDOR Phase 3 trial results have been published in the online version of Clinical Cancer Research.
- Motley Fool
Lantheus Holdings Inc (LNTH) Q4 2020 Earnings Call Transcript
LNTH earnings call for the period ending December 31, 2020.
- Benzinga
Recap: Lantheus Holdings Q4 Earnings
Shares of Lantheus Holdings (NASDAQ:LNTH) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 79.41% year over year to $0.07, which beat the estimate of $0.01. Revenue of $94,152,000 up by 5.38% year over year, which beat the estimate of $92,230,000. Guidance The upcoming fiscal year's EPS expected to be between $0.34 and $0.39. The upcoming fiscal year's revenue expected to be between $385,000,000 and $400,000,000. Details Of The Call Date: Feb 25, 2021 View more earnings on LNTH Time: 04:30 PM ET Webcast URL: https://edge.media-server.com/mmc/p/fnf394tc Recent Stock Performance Company's 52-week high was at $20.29 52-week low: $8.67 Price action over last quarter: Up 69.92% Company Profile Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its imaging products and agents assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its agents are typically non-radioactive compounds that are used in diagnostic procedures, such as cardiac ultrasounds, or echocardiograms, x-ray imaging used by physicians to progress the clarity of the diagnostic image. The company's portfolio of imaging products includes medical radiopharmaceuticals such as DEFINITY, TechneLite, Xenon Xe 133 Gas, Cardiolite, and Neurolite. Its revenue is generated from the sales of diagnostic imaging agents to wholesalers, distributors radiopharmacy and directly to hospitals and clinics predominantly in the United States. See more from BenzingaClick here for options trades from BenzingaSTORE Capital: Q4 Earnings Insights12 Information Technology Stocks Moving In Thursday's After-Market Session© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
